NCT06422520 2026-04-06
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting
BeOne Medicines
Replimune Inc.
BeOne Medicines
Sonnet BioTherapeutics
Guangdong Hengrui Pharmaceutical Co., Ltd
D2M Biotherapeutics Inc.
Cullinan Therapeutics Inc.
Broadenbio Ltd., Co.
Quanta Therapeutics
Radboud University Medical Center
Innolake Biopharm
Shanghai East Hospital